An open label study of clobetasol propionate 0.05% and betamethasone valerate 0.12% foams in the treatment of mild to moderate acne keloidalis

Cutis. 2005 Jun;75(6):317-21.

Abstract

Acne keloidalis (AK) is a disease affecting primarily African American men. Topical steroids are a widely accepted treatment of AK; however, no studies have been published investigating their effectiveness. The purpose of this open-label study was to assess the efficacy and tolerability of clobetasol propionate 0.05% and betamethasone valerate 0.12% foams in the treatment of AK in 20 African American patients. These patients were treated for 8 to 12 weeks using a pulsed-dose regimen. We found topical clobetasol propionate foam to be effective in improving AK, and our patients found the foam vehicle to be cosmetically acceptable.

Publication types

  • Clinical Trial

MeSH terms

  • Acne Keloid / drug therapy*
  • Administration, Topical
  • Adult
  • Anti-Inflammatory Agents / administration & dosage*
  • Anti-Inflammatory Agents / adverse effects
  • Betamethasone Valerate / administration & dosage*
  • Betamethasone Valerate / adverse effects
  • Black or African American
  • Clobetasol / administration & dosage
  • Clobetasol / adverse effects
  • Clobetasol / analogs & derivatives*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Quality of Life
  • Scalp Dermatoses / drug therapy*
  • Treatment Outcome

Substances

  • Anti-Inflammatory Agents
  • Betamethasone Valerate
  • Clobetasol